JXJinlong Xu

Jinlong Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinlong Xu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Triboelectric Mat Multimodal Sensing System (TMMSS) Enhanced by Infrared Image Perception for Sleep and Emotion‐Relevant Activity Monitoring

    by Jinlong Xu, Xinge Guo, Zixuan Zhang, Huajun Liu, Chengkuo Lee

    To implement digital‐twin smart home applications, the mat sensing system based on triboelectric sensors is commonly used for gait information collection from daily activities. Yet traditional mat sensing systems often miss upper body motions and fail to adequately project these into the virtual realm, limiting their specific application scenarios. Herein, triboelectric mat multimodal sensing system is designed, enhanced with a commercial infrared imaging sensor, to capture diverse sensory information for sleep and emotion‐relevant activity monitoring without compromising privacy. This system generates pixel‐based area ratio mappings across the entire mat array, solely based on the integral operation of triboelectric outputs. Additionally, it utilizes multimodal sensory intelligence and deep‐learning analytics to detect different sleeping postures and monitor comprehensive sleep behaviors and emotional states associated with daily activities. These behaviors are projected into the metaverse, enhancing virtual interactions. This multimodal sensing system, cost‐effective and non‐intrusive, serves as a functional interface for diverse digital‐twin smart home applications such as healthcare, sports monitoring, and security.


  • Top Cited Papers

    Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

    by Jing Pan, Yue Tan, Lingling Shan, Samuel Seery, Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, et al.

    Refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL) patients have poor prognoses, due to the lack of effective salvage therapies. Recently, CD7-targeting chimeric antigen receptor (CAR)-T therapies show efficacy in patients with r/r T-ALL, but relapse with CD7 loss is common. This study evaluates a CD5-gene-edited CAR-T cell therapy targeting CD5 in 19 r/r T-ALL patients, most of whom had previously failed CD7 CAR-T interventions. CAR-T products were derived from previous transplant donors (Cohort A) or newly matched donors (Cohort B). Primary endpoints were dose-limiting toxicity at 21 days and adverse events within 30 days. Secondary endpoints were responses, pharmacokinetics and severe adverse events after 30 days. A total of 16 received infusions, 10 at target dose of 1 × 106 kg−1. All encountered grade 3–4 cytopenias and one had a grade 3 infection within 30 days. All patients (100%) achieved complete remission or complete remission with incomplete blood count recovery by day 30. At a median follow-up of 14.3 months, four received transplantation; three were in remission and one died of infection. Of 12 untransplanted patients, 2 were in remission, 3 relapsed, 5 died of infection and 2 of thrombotic microangiopathy. CAR-T cells persisted and cleared CD5+ T cells. CD5− T cells, mostly CD5-gene-edited, increased but remained below normal levels. These results suggest this CD5-specific CAR-T intervention has a high remission rate for T-ALL patients. Evidence also suggests the risk of late-onset severe infection may be mitigated with consolidative transplantation. This study provides insights that could help to optimize this promising intervention. ClinicalTrials.gov registration: NCT05032599.